Drug intelligence / Profile preview

HydroLenz

Development stage: Discontinued
Lead developer: PromiSight
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Ophthalmic

Overview

HydroLenz is a novel hydrogel-based formulation developed by PromiSight for the prevention of cataracts following pars plana vitrectomy. During vitrectomy, the removal of the vitreous humor often leads to increased oxygen tension or other physiological changes that cause the natural lens to become opaque. HydroLenz is administered as an intraocular injection at the conclusion of the surgical procedure to serve as a protectant for the lens. The goal of this therapy is to maintain lens clarity and preclude the need for subsequent cataract surgery and intraocular lens replacement. It is currently being evaluated in a Phase 1 clinical trial to assess safety and preliminary efficacy in humans.

Brand names: HydroLenz
Other names: HydroLenz

Beyond the preview

Go deeper on HydroLenz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HydroLenz.

Explore the full profile